Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: a pilot prospective study
- PMID: 23361307
- DOI: 10.1007/s12094-012-0990-0
Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: a pilot prospective study
Abstract
Purpose: To analyze the use of proteomic profiles to discriminate healthy from patients with colorectal liver metastases (CLM) and to predict neoplastic recurrence after CLM resection.
Methods: From April 2005 to October 2008, 70 patients operated for first curative resection of CLM and 60 healthy controls underwent determination of preoperative serum proteomic profile. We performed a preliminary training with patients and controls and obtained a classification system based on these patients' proteomic profiles training. The system was then tested about the ability to predict the colon versus rectum origin, metachronous or synchronous appearance, risk of recurrence after CLM resection and whether a sample was from a control or a CLM patient.
Results: Sensitivity, specificity, positive and negative predictive values for detecting CLM patients were 75, 100, 100 and 54.6 %, respectively. Best CLM appearance time identification was 50 % and primary tumor origin identification was 62.5 %. Best classifications of neoplastic recurrence within the first year after CLM resection and during the follow-up period were 47.5 and 45 %, respectively. Larger training sets and prevalence-based training sets led to better classification of patients and characteristics.
Conclusion: Proteomic profiles are a promising tool for discriminating CLM patients from healthy patients and for predicting neoplastic recurrence.
Similar articles
-
Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement.Tumour Biol. 2015 Dec;36(12):9839-47. doi: 10.1007/s13277-015-3729-z. Epub 2015 Jul 11. Tumour Biol. 2015. PMID: 26162539 Free PMC article.
-
Efficacy of Adjuvant Chemotherapy According to the Classification of Recurrence Risk Based on Systemic Inflammatory Markers in Patients With Liver Metastases of Colorectal Cancer.Anticancer Res. 2019 Sep;39(9):5039-5045. doi: 10.21873/anticanres.13695. Anticancer Res. 2019. PMID: 31519612
-
Prognostic Impact of Adjuvant Chemotherapy after Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases.Dig Surg. 2018;35(3):187-195. doi: 10.1159/000478791. Epub 2017 Aug 19. Dig Surg. 2018. PMID: 28848205
-
Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?World J Gastroenterol. 2015 Jun 14;21(22):7014-21. doi: 10.3748/wjg.v21.i22.7014. World J Gastroenterol. 2015. PMID: 26078580 Free PMC article. Review.
-
Resection of liver metastases from colorectal cancer. Indications and results.Dis Colon Rectum. 1994 Nov;37(11):1078-82. doi: 10.1007/BF02049807. Dis Colon Rectum. 1994. PMID: 7956573 Review.
Cited by
-
Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases.Transl Oncol. 2016 Oct;9(5):445-452. doi: 10.1016/j.tranon.2016.08.002. Transl Oncol. 2016. PMID: 27751349 Free PMC article.
-
Prognostic circulating proteomic biomarkers in colorectal liver metastases.Comput Struct Biotechnol J. 2023 Mar 11;21:2129-2136. doi: 10.1016/j.csbj.2023.03.011. eCollection 2023. Comput Struct Biotechnol J. 2023. PMID: 36992914 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous